Acumen Pharmaceuticals to present Phase 2 trial data at CTAD
Tweet Send to a Friend
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present three poster presentations at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




